NCT06445517View on ClinicalTrials.gov

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

February 28, 2027

Conditions
Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
Interventions
DRUG

ISM8207

Pharmaceutical formulation: Capsules Mode of Administration: Oral

Trial Locations (2)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

200025

RECRUITING

Shanghai Jiao Tong University School of Medicine-Ruijin Hospital, Shanghai

All Listed Sponsors
lead

InSilico Medicine Hong Kong Limited

INDUSTRY